Valenta Pharm JSC

Quick facts

Marketed products

• Afobazole · Other
• Arlevert · Other
• Ranquilon · Other
• Vespireit · Other

Phase 3 pipeline

• Hydroxymethylquinoxalindioxyde
  Hydroxymethylquinoxalindioxyde is a quinoxaline derivative that likely acts as an antioxidant or free radical scavenger to reduce oxidative stress-related cellular damage.
• Imidazolyl ethanamide pentandioic acid
  Imidazolyl ethanamide pentandioic acid is a small-molecule compound that likely acts as a metabolic modulator or cellular signaling agent, though its precise mechanism remains proprietary.
• XC8 · Diabetes
  XC8 is a small molecule that targets the SGLT2 receptor.

Phase 2 pipeline

• Grammidin with anesthetic
• Septolete Total

Phase 1 pipeline

• Antareit · Other
• Aterixen · Other
• Grammidin, a metered dose topical spray
• Grammidin neo
• Grammidin with anesthetic neo
• Trimedat®

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Valenta Pharm JSC portfolio CI brief
• Valenta Pharm JSC pipeline updates RSS